ArticleDermato-endocrinology2012
Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to date.
Article in Dermato-endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- [Consensus statement of the Austrian Society for Rheumatology and Rehabilitation on the management of increased cardiovascular risk in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis].Wiener klinische Wochenschrift · 2026Article
- Effects of biological agents on lipid profile and hemogram parameters in patients with psoriasis.Archives of dermatological research · 2025Article
- Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025Review
- Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review.Vascular health and risk management · 2024Review
- Evidence for Biologic Drug Modifying Anti-Rheumatoid Drugs and Association with Cardiovascular Disease Risk Mitigation in Inflammatory Arthritis.Rheumatic diseases clinics of North America · 2023Review
- Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics.Current atherosclerosis reports · 2021Review
- Interleukin 23 and autoimmune diseases: current and possible future therapies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Review
- The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease.Gastroenterology & hepatology · 2019Article
- Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study.Cardiovascular research · 2019Observational
- IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.Nature reviews. Gastroenterology & hepatology · 2019Review
- A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases.JGH open : an open access journal of gastroenterology and hepatology · 2018Review
- Prostaglandin E2 and IL-23 interconnects STAT3 and RoRγ pathways to initiate Th17 CD4Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018Review
- Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.Human vaccines & immunotherapeutics · 2018Article
- Comorbidities in Spondyloarthritis.Frontiers in medicine · 2018Review
- The role of IL-23 and the IL-23/TJournal of the European Academy of Dermatology and Venereology : JEADV · 2017Review
- The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis.International journal of molecular sciences · 2017Review
- Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report.JAAD case reports · 2015Article
- Preclinical development of AMG 139, a human antibody specifically targeting IL-23.British journal of pharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Safety concerns have been raised regarding possible association of major adverse cardiovascular events (MACEs) with use of anti-IL-12/23 biologic agents for the treatment of chronic plaque psoriasis (CPP). Ten MACEs have been recorded in actively-treated patients during the placebo-controlled phase of phase II and III studies compared with zero events in placebo-treated patients, along with a total of 53 MACEs (26 ustekinumab, 27 briakinumab) and five cardiovascular deaths (1 ustekinumab, 4 briakinumab) across all phases of these studies. Two industry-independent meta-analyses of randomized, double-blind, placebo-controlled, monotherapy trials calculated risk for MACEs. One detected statistically significant increase in cardiovascular risk using Peto method (p = 0.04), while the other utilized Mantel-Haenszel fixed-effects model with absolute risk differences as effect measure, but did not achieve significance (p = 0.11). Statistical theory reports that Peto method is more suitable for meta-analyses of studies with baseline event rates of 1% or less and randomization ratios ranging from 1:5 to 1:1 as is the case in these meta-analyses. Potential of anti-IL-12/23 biologic agents to further increase cardiovascular morbidity cannot be excluded and a class effect cannot be denied. Clinicians should screen CPP patients for manageable cardiovascular risk factors before initiating anti-IL-12/23 agents along with intensive monitoring of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.